Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416031 | 0.84 | DPP4 (0.52) | SRCDPP4DPP8ANPEPTDP1 | |
| Hydrochloric Acid SCHEMBL7424508 | 0.83 | DPP4 (0.53) | SRCDPP4DPP8ANPEPTDP1 | |
| SCHEMBL7426176 | 0.79 | DPP4 (0.48) | SRCDPP4DPP8ANPEPTDP1 | |
| Hydrochloric Acid SCHEMBL7424349 | 0.78 | DPP4 (0.49) | SRCDPP4DPP8ANPEPTDP1 | |
| SCHEMBL28000354 | 0.76 | DPP4 (0.45) | SRCDPP4DPP8ANPEPTDP1 | |
| SCHEMBL11658493 | 0.73 | SRC (0.52) | SRCDPP4DPP8ANPEPTDP1 | |
| SCHEMBL5819393 | 0.73 | DPP4 (0.54) | SRCDPP4DPP8ANPEPCYP1A2 | |
| SCHEMBL672896 | 0.71 | SRC (0.70) | SRCANPEPTDP1L3MBTL1KDM4E | |
| SCHEMBL17559995 | 0.71 | SRC (0.44) | SRCDPP4DPP8ANPEPTDP1 | |
| Piperazine SCHEMBL8466410 | 0.71 | SRC (0.57) | SRCANPEPTDP1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018134335-A1 | SUBSTITUTED IMIDAZOPYRIDINPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-26 | — | — | WO | disclosed |
| CN-105008364-B | substituted Imidazopyridazines | 拜耳制药股份公司 | 2017-11-07 | — | — | CN | disclosed |
| EP-2951175-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINYLAMINO-INDAZOLES | Bayer Pharma AG (DE) | 2017-10-04 | — | — | EP | disclosed |
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9556181-B2 | Substituted pyrazolopyrimidinylamino-indazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| CN-103649087-B | Substituted imidazopyridine and intermediate thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-30 | — | — | CN | disclosed |
| US-9388140-B2 | Substituted benzimidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-9382255-B2 | Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-05 | — | — | US | disclosed |
| EP-2694500-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | disclosed |
| EP-2691375-A1 | SUBSTITUTED BENZIMIDAZOLES | Bayer Intellectual Property GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| WO-2013174743-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174735-A1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| CN-103370318-A | Substituted imidazopyridazines | BAYER IP GMBH | 2013-10-23 | — | — | CN | disclosed |
| EP-2614063-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012130905-A1 | SUBSTITUTED BENZIMIDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BUB1, TTBK1, BUB1B | SRC 534/4885DPP4 2242/4885DPP8 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.